CLINICAL TRIAL: REBIF (IFN BETA-1A) AND BETASERON (IFN BETA-1B) IN IFN-NAIVE MS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 贝塔干扰素在许多临床措施上都显示出明显的疗效。然而，这些药物已知会引起某些不良反应，可能导致患者停止治疗。注射痛是一种不良反应。注射疼痛是所有可注射DMT的临床问题，包括REBIF(干扰素β-1a)和倍他舒坦。Rebif的重新配方目前正在发射前进行测试。这项研究将通过比较研究期间与全量注射治疗相关的注射后30分钟内的平均最大疼痛来评估这种新配方的REBIF和倍他龙在RRMS受试者中的耐受性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Interferon beta has demonstrated clear efficacy on a number of clinical measures. However, these agents are known to cause certain adverse effects that can lead to patients discontinuing their treatment. Injection pain is one type of adverse effect. Injection pain is a clinical concern with all injectable DMTs including Rebif(interferon beta-1a) and Betaseron¿. A reformulation of Rebif¿ is currently being tested prior to launch. This study will evaluate the tolerability of this new formulation of Rebif¿ and Betaseron¿ in subjects with RRMS by comparing the mean maximum pain within 30 minutes post injection associated with full-dose injection therapy over the study period.